VolitionRX
150 Orchard Road
Orchard Plaza 08-02
Singapore
238841
Website: http://www.volitionrx.com/
Email: info@volitionrx.com
265 articles about VolitionRX
-
VolitionRx Limited Executes a Contract for Clinical Trial Program in Lung Cancer
5/7/2019
VolitionRx Limited announced that it has added to its extensive clinical trial program with the execution of a contract under the previously announced Memorandum of Understanding, to conduct its first large-scale lung cancer study in conjunction with the prestigious National Taiwan University.
-
VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call and Business Update
5/6/2019
Conference call to take place Thursday, May 9, 2019 at 8:30 am Eastern time
-
VolitionRx Limited Hosts Capital Markets Day at the New York Stock Exchange and Issues Company Update Report
4/9/2019
VolitionRx Limited hosted a Capital Markets Day at the New York Stock Exchange to update interested parties on its recent progress.
-
VolitionRx Limited Signs Memorandum of Understanding with Texas A&M University for Potential Collaboration to Develop Nu.QTM Veterinary Diagnostics
4/9/2019
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a nonbinding Memorandum of Understanding ("MOU") through its wholly-owned subsidiary, Belgian Volition SPRL, with Texas A&M University, a member of The Texas A&M University System. Pursuant to the terms of the MOU, the parties will explore the feasibility of a collaborative research relationship.
-
VolitionRx Limited Extends Clinical Trial Program in Lung Cancer
4/3/2019
VolitionRx Limited announced that it has added to its extensive clinical trial program with the execution of a non-binding Memorandum of Understanding, through its wholly-owned subsidiary, Belgian Volition SPRL, to conduct its first large-scale lung cancer study in conjunction with the prestigious National Taiwan University.
-
VolitionRx Limited to Present at Conferences in March & April 2019
3/25/2019
VolitionRx Limited announced that its Executive Vice President, Investor Relations, Scott Powell, is scheduled to present at three conferences in March and April 2019.
-
VolitionRx Limited Announces Full Fiscal Year 2018 Financial Results and Business Update
3/13/2019
Conference call to discuss financial and operational results scheduled for Thursday, March 14 at 8:30 a.m. U.S. Eastern Time
-
VolitionRx Limited Schedules Full Year 2018 Earnings Conference Call and Business Update
3/7/2019
VolitionRx Limited announced it will host a conference call on Thursday, March 14 at 8:30 a.m. Eastern time to discuss its financial and operating results for the fourth quarter and full year 2018, in conjunction with the filing of its annual report on Form 10-K for the fourth quarter and full year ended December 31, 2018.
-
VolitionRx Limited Announces Third Quarter 2018 Financial Results and Business Update
11/7/2018
VolitionRx Limited today announced financial results and a business update for the quarter ended September 30, 2018.
-
Preliminary Data from Study Demonstrates 94% Accuracy in Detecting Aggressive Prostate Cancer
8/13/2018
Announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility of Volition's Nu.Q™ assays to diagnose men with high-grade prostate cancer.
-
VolitionRx Limited Announces Second Quarter 2018 Financial Results and Business Update
8/13/2018
VolitionRx Limited announced financial results and a business update for the quarter ended June 30, 2018.
-
VolitionRx Limited Announces Completion of Sample Collection in Endometriosis Study
8/9/2018
VolitionRx Limited announced that the 3-year sample collection has been completed in the prospective study undertaken in collaboration with the University of Oxford, England to assess Volition's proprietary Nu.Q™ platform technology
-
VolitionRx Announces $9 Million Private Placement
8/8/2018
VolitionRx Limited announced that it has entered into a definitive agreement with an existing accredited investor related to a private placement offering (PIPE) of 5 million shares of Volition common stock at a price of $1.80 per share
-
VolitionRx Limited Schedules Second Quarter 2018 Earnings Conference Call and Business Update
8/7/2018
Conference call to take place Tuesday, August 14, 2018 at 8:30 am Eastern time
-
VolitionRx's First Research Use Only Product Is "On-The-Shelf" Today
8/1/2018
VolitionRx Limited announced that its first product the "Total Nu.Q™ Assay" research use only (RUO) kit, is ready and available for purchase through Active Motif, its Global Sales and Distribution Partner
-
Volition Secures Additional $700,000 Non-Dilutive Funding from the Walloon Region
7/2/2018
VolitionRx Limited announced that it has been awarded additional non-dilutive funding of approximately $700,000 from the Walloon Regional Government.
-
VolitionRx Limited to Attend the Bank of America Merrill Lynch 2018 Health Care Conference from May 15-17, 2018
5/14/2018
VolitionRx Limited (NYSE American: VNRX) ("Volition") today announced its participation in the Bank of America Merrill Lynch 2018 Health Care Conference being held from May 15-17, 2018 at the Encore Hotel in Las Vegas, NV.
-
VolitionRx Limited Schedules First Quarter 2018 Earnings Conference Call and Business Update
5/4/2018
VolitionRx Limited announced it will host a conference call on Friday, May 11 at 8:30 a.m. Eastern time
-
VolitionRx Announces Pricing of $8.4 Million Public Offering of Common Stock
3/9/2018
VolitionRX Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers, announced today the pricing of its previously announced underwritten public offering of 3,500,000 shares of common stock at a public offering price of $2.40 per share.
-
VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board
3/7/2018
VolitionRX Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has further strengthened its Scientific Advisory Board with the addition of Dr. Lee-Jen Wei, a professor of Biostatistics at Harvard University.